U.S.
Senate committee chair: Mylan?s response on
EpiPen price hike ?incomplete?
WASHINGTON (Reuters) - The chairman of the
U.S. Senate Judiciary
committee probing Mylan NV's
EpiPen price hike on Friday said its
response to his query was "incomplete," and called on the drugmaker to give more details over how much government health insurance programs pay for the allergy treatment.
